Validation of the lung inmune prognostic (LIPI) index in first-line immunotherapy treatment of small cell lung carcinoma

被引：0

作者：

Cruz Castellanos, P. ^{[1
]}

Gutierrez Sainz, L. ^{[2
]}

Fernandez Franco, L. ^{[3
]}

Rogado, J. ^{[4
]}

Mielgo Rubio, X. ^{[5
]}

Collazo Lorduy, A. ^{[6
]}

Riesco Montes, B. ^{[7
]}

Traseira Puchol, C. ^{[8
]}

Simon, S. ^{[9
]}

Falagan Martinez, S. ^{[10
]}

Chara Velarde, L. E. ^{[11
]}

Martin Fernandez, A. M. ^{[12
]}

Cabezon Gutierrez, L. ^{[13
]}

Lopez Martin, A. ^{[14
]}

Sanchez Sanchez, J. L. ^{[15
]}

Cerezo Gonzalez, S. ^{[16
]}

Viana, A. ^{[17
]}

Munoz-Rodriguez, J. R. ^{[18
]}

机构：

[1] Hosp Univ Cuidad Real, Dept Med Oncol, Ciudad Real, Spain

[2] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain

[3] Hosp Virgen Salud, Dept Oncol, Toledo, Spain

[4] Hosp Univ Infanta Leonor, Dept Med Oncol, Madrid, Spain

[5] Hosp Univ Fdn Alcorcon, Dept Med Oncol, Madrid, Spain

[6] Univ Hosp Puerta Hierro Majadahonda, Oncol Med, Majadahonda, Spain

[7] Complejo Hosp Univ Albacete, Dept Oncol, Albacete, Spain

[8] Hosp Henares, Dept Med Oncol, Coslada, Spain

[9] Hosp Virgen Cruz Cuenca, Dept Med Oncol, Hosp Gen Virgen Luz, Cuenca, Spain

[10] Hosp Univ Infanta Sofia, Dept Med Oncol, San Sebastian Los Reyes, Spain

[11] Hosp Univ Guadalajara, Dept Med Oncol, Guadalajara, Spain

[12] Hosp Henares, Dept Med Oncol, Coslada, Spain

[13] Hosp Univ Torrejon, Dept Med Oncol, Torrejon De Ardoz, Spain

[14] Hosp Univ Severo Ochoa, Dept Med Oncol, Madrid, Spain

[15] Hosp Gen Almansa, Dept Med Oncol, Almansa, Spain

[16] Hosp Gen Mancha Ctr, Med Oncol, Alcazar De San Juan, Spain

[17] Gen Hosp Nuestra Senora Prado, Med oncol, Toledo, Spain

[18] Hosp Gen Univ Ciudad Real, Med Oncol, Ciudad Real, Spain

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1900

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1809P

引用

页码：S1073 / S1073

页数：1

共 50 条

[21] First-line treatment for non-small cell lung cancer
Pinn, Stephen
BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (01) : 10 - 10
[22] Topotecan in the first-line treatment of small-cell lung cancer
Wolf, M
ONKOLOGIE, 2000, 23 : 13 - 17
[23] First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?
Uprety, Dipesh
Remon, Jordi
Peters, Solange
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (04)
[24] First-line combination immunotherapy for metastatic non-small cell lung cancer
Chen, Yuh-Min
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2020, 83 (05) : 433 - 441
[25] Lung Immune Prognostic Index (LIPI): Prognostic predictor for patients with extensive-stage small-cell lung cancer
Majidova, Nargiz
Seyyar, Mustafa
Guren, Ali Kaan
Kocaaslan, Erkam
Kircali, Muhammed Fatih
Sever, Nadiye
Erel, Pinar
Agyol, Yesim
Pacaci, Burak
Tunc, Mustafa Alperen
Bayoglu, Ibrahim Vedat
MARMARA MEDICAL JOURNAL, 2025, 38 (01): : 24 - 28
[26] Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma
Song, Jiangdian
Tian, Jie
Zhang, Lina
Qu, Xiujuan
Qian, Wei
Zheng, Bin
Zhang, Lina
Zhao, Jia
Niu, Meng
Zhou, Mu
Cui, Lei
Liu, Yunpeng
Zhao, Mingfang
EUROPEAN RADIOLOGY, 2019, 29 (05) : 2388 - 2398
[27] Correction to: Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer
Puneet Saxena
Pawan Kumar Singh
Prabhat Singh Malik
Navneet Singh
Current Treatment Options in Oncology, 2020, 21
[28] The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced Non Small Cell Lung Cancer
Rocco, Danilo
Della Gravara, Luigi
Battiloro, Ciro
Gridelli, Cesare
EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (03) : 303 - 309
[29] Immunotherapy as first-line treatment in metastatic non-small cell lung cancer: A single center experience
Rauthan, A.
Patil, P.
Lahkar, K.
Murthy, N. Y.
Vundemodalu, P.
Ashwath, R.
Jomi, C.
ANNALS OF ONCOLOGY, 2022, 33 : S1576 - S1576
[30] Small-cell lung carcinoma with ovarian metastasis 4 years after the first-line treatment
Jun Kitazawa
Akimasa Takahashi
Mao Uemura
Yoshihiko Hayashi
International Cancer Conference Journal, 2019, 8 : 109 - 113

← 1 2 3 4 5 →